We aim to restore meningeal lymphatic function to treat CNS disease by boosting waste clearance and dampening neuroinflammation. Building on evidence that lymphatic flow declines with age and that targeted VEGFR3 activation expands capacity and improves synaptic physiology, we will deploy lymphatic-specific VEGF-C (LS-VEGF-C) to “unclog” CNS clearance pathways and test its impact on amyloid/tau burden and circuit function in rigorous preclinical models, with translational imaging endpoints aligned to emerging human data.
In an 18-month runway, we will deliver a definitive PK package, non-GLP CNS toxicology, and a head-to-head efficacy study versus an active comparator to establish proof of concept. This package de-risks exposure, safety, and translational efficacy and provides a clear line of sight to IND-enabling studies. Early-stage investors we consulted confirm this meets the bar for next-round financing to advance into IND preparation.